Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer

Inclusion Criteria: * Men \>18 years * Histologically confirmed prostate adenocarcinoma * Low or low-intermediate risk prostate cancer, defined as Clinical stage T1-2b, Gleason Score \<=6, and PSA \<15 ng/mL, OR Clinical stage T1-2b, Gleason Score 7, and PSA \<=10 ng/mL Exclusion Criteria: * Prior pelvic radiotherapy * Anticoagulation medication (if unsafe to discontinue for gold seed insertion) * Diagnosis of bleeding diathesis * Presence of a hip prosthesis * Pelvic girth \>40cm - Large prostate (\>90cm3) on imaging * Severe lower urinary tract symptoms (International Prostate Symptom Score \>19 or nocturia \>3)